HFA 2020: Eligibility for Sacubitril/Valsartan in HF across the EF Spectrum

Published: 10 Jul 2020

  • Views:

    Views Icon 256
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Dr Gianluigi Savarese (Karolinska University Hospital, Stockholm, SE) discusses real world data from the Swedish Heart Failure Registry, investigating the eligibility of sacubitril/valsartan in heart failure across the ejection fraction (EF) spectrum.


1. What is the rationale for the study and what makes it unique?

2. What was the design of the study?

3. How does this study address the HF therapeutic deficit in women compared with men?

4. How did you define mid-range EF?

5. What were your findings?

6. What are the clinical implications?

7. What further research is needed?

8. What is the study's take-home message for practising clinicians?


Recorded remotely from Stockholm, 2020. 

Interviewer: Mirjam Boros

Recording Editor: Natascha Wienand